• by Bruce Carlson
  • April 28 2017
  • EMR


The State of the EMR Market in 2017

The State of the EMR Market in 2017

The now $28 billion-dollar EMR market is undergoing changes, according to a new report from Kalorama Information. Physician adoption of medical records s is high but usage of EHR might be limited. Providers are switching vendors. And a new administration, no fans of EMR payment schemes and use standards, may bring regulation and payment changes. This article also addresses market share in the electronic medical records market and top EHR vendors.


Promise of Fast Growth Propels Molecular Technologies in Fighting Infections

Promise of Fast Growth Propels Molecular Technologies in Fighting Infections

Molecular infectious disease tests detect active and latent patient infections by targeting genetic sequences specific to pathogens, typically bacteria or viruses, but also fungi and parasites. Tests that utilize these methods experience faster revenue growth and will compete better on the world market, according to Kalorama's recent study on the molecular infectious disease testing market.


Want a Vision of The POC Diagnostics Market in the Future? Look No Further Than Star Trek

Want a Vision of The POC Diagnostics Market in the Future?   Look No Further Than Star Trek

Inspired by Qualcom's prize, two innovative POC products won a competition to develop Gene Roddenberry-influenced diagnostic devices. These devices may point to the future of the POC diagnostics market, the high-growth IVD test category that provides near-patient test results.


Retail Clinics Bring Healthcare to Consumers, While Other Facilities Wait for Patients

Retail Clinics Bring Healthcare to Consumers, While Other Facilities Wait for Patients

Retail clinics are a game-changer in healthcare, as this blog notes., as they operate where consumers are. The retail clinic market reached 1.4 billion in 2017, according to Kalorama's latest report. This reversal of the flow of healthcare delivery hasn't gone unnoticed by physicians, hospitals, insurance companies and device companies.


Qiagen Adds to Leading Molecular Cancer Menu with FDA-Cleared JAK2 Test Kit

Qiagen Adds to Leading Molecular Cancer Menu with FDA-Cleared JAK2 Test Kit

The U.S. Food and Drug Administration (FDA) recently approved Qiagen’s ipsogen JAK2 RGQ PCR Kit for detection of the V617F mutation on the JAK2 gene associated with the myeloproliferative disorder polycythemia vera. The cancer test kit assists patient evaluation for the particular form of leukemia and is routinely tested in myeloproliferative neoplasms (MPNs) negative for mutation in the BCR-ABL gene. Kit availability for JAK2 testing will make the test more widely available to health systems for the implementation of personalized medicine for leukemia patients.


Molecular Diagnostics Faces Competition for Future Point of Care Testing in Developing World

Molecular Diagnostics Faces Competition for Future Point of Care Testing in Developing World

The sensitivity and specificity of nucleic acid analytes provide molecular diagnostics key advantages in clinical practice, particularly in critical health situations. Nucleic acid amplification (NAATs) or molecular tests are now open to routine and distributed use in healthcare thanks to advancements in microfluidics and molecular reagents. As molecular diagnostics enter point-of-care (POC) settings, cost becomes a key issue in comparison to predominantly used and cheaply performed rapid immunoassays.